Enhancement of 5-aminolaevulinic acid-induced photodynamic therapy in normal rat colon using hydroxypyridinone iron-chelating agents. by Curnow, Alison et al.
Brtish Jourmal of Cancer (1998) 78(10). 1278-1282
C 1998 Cancer Research Campaign
Enhancement of 5-aminolaevulinic acid-induced
photodynamic therapy in normal rat colon using
hydroxypyridinone iron-chelating agents
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Summary Currently, the clinical use of 5-aminolaevulinic acid (ALA)-induced protoporphyrin IX (PPIX) for photodynamic therapy (PDT) is
limited by the maximum tolerated oral ALA dose (60 mg kg-'). This study investigates whether hydroxypyridinone iron-chelating agents can
be used to enhance the tissue levels of PPIX, without increasing the administered dose of ALA. Quantitative charge-coupled device (CCD)
fluorescence microscopy was employed to study PPIX fluorescence pharmacokinetics in the colon of normal Wistar rats. The iron chelator,
CP94, when administered with ALA was found to produce double the PPIX fluorescence in the colonic mucosa, compared with the same dose
of ALA given alone and to be more effective than the other iron chelator studied. CP20. Microspectrofluorimetric studies demonstrated that
PPIX was the predominant porphyrin species present. PDT studies conducted on the colonic mucosa showed that the simultaneous
administration of 100 mg kg-' CP94 i.v. and 50 mg kg-' ALA i.v. produced an area of necrosis three times larger than similar parameters
without the iron-chelating agent with the same light dose. It is possible, therefore, to increase the amount of necrosis produced by ALA-
induced PDT substantialty, without increasing the administered dose of ALA, through the simultaneous administration of the iron-chelating
agent, CP94.
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Photodynamic therapy (PDT) is a non-thermal technique in which
a preadministered photosensitizer is activated w-ith light of a
specific wavelength. so that a cytotoxic species can be formed
from molecular oxygen. thus. producing localized tissue necrosis
(Bow-n. 1989).
The sNstemic administration of 5-aminolaevulinic acid (ALA)
is a relatively new approach in PDT. This naturallv occurring
compound enters the nonnal. mammalian. tetrapvrrole biosyn-
thetic pathway. bypassing the normal. negative-feedback inhibi-
tion of its production (Bonnett. 1995). This results in the increased
production and build up of protoporphxrin IX (PPIX) (a naturally
occumnri photosensitizer). as the final step of the pathway [the
chelation of ferrous iron (Fe'-> to PPIX to form haem] is relativ ely
slow (Strver. 1988).
Benefits of ALA-induced PDT include reduced skin photosensi-
tivitv (1 or 2 days compared A ith sex eral w'eeks with other photo-
sensitizers) as all the intermediates elevated by this modalitx are
rapidly cleared, being, naturally occurring compounds (Kennedy
and Pottier. 1992). Topical or oral administration is possible. with
an intravenous preparation currently being investigated. Repeat
treatments are also possible (if necessary) after only a few days
(MacRobert. 1994). Preliminarv clinical studies. however. have
only shown superficial necrosis with the maximum tolerated oral
dose (60 mg kg-1). Methods to increase the effectiveness of this
treatment modalitv. waithout increasing the administered ALA
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dose. are therefore beinc inv-estigated. 'ith the effects of iron-
chelating agents being studied in this paper.
The hydroxypy ridinones are a relativels newa series of iron-
chelatincg agents. They can be administered orally and enter the
intracellular iron pools rapidlN. being both neutrally charged and
of lowa molecular weig-ht (Hoy es and Porter. 1993). Oririnallv
developed to supersede desferrioxamine for the treatment of
thalassaemia and other disorders of iron overload. the hydroxv-
pyridinones are now beincg investicated to enhance ALA-induced
PDT. They do this by chelatincg iron. thus reducincg the conversion
of PPIX to haem. resultincg in an even greater accumulation of
PPIX and. thus. a greater photodynamic effect (Chanc et al. 1997).
Tw o hVdroxypyridinones are studied in this paper: the 1.2-
dimethyl derixative (CP2O) and the l.2-diethxl derivative (CP94).
Both of these compounds has-e been given to patients with iron
overload v ithout sicnificant toxicity and produced rapid and
effective iron mobilization (Brittenham. 1992).
MATERIALS AND METHODS
Chemicals
ALA powder (ALA.HC1. 99% purity. DUSA Pharmaceuticals.
NY. USA) was dissolved in physiological strength. phosphate-
buffered saline (PBS. pH 2.8) and administered intravenously
('aith a concentration of 50 mc, ml and a maximum xolume of
0.2 ml). The iron chelators. CP2O and CP94. w'ere synthesized and
kindly donated in powder form by the Department of Pharmacy.
Kinas Collegye. London. UK (90% and 95% purity respectively).
These were also prepared in PBS and administered intravenously
('aith a concentration of 100 mg, ml-' and a maximum volume of
0.2 ml). Separate syrines -ere always used for the iron chelator
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Figure 1 Fluorescence (arbitrary units) of the colonic mucosa and muscle as a function of time (min) with the following treatment regimes: (A) 50 mg kg-, ALA
i.v., (B) 100 mg kg- CP20 or CP94 i.v., (C) simultaneous administration of 50 mg kg-' ALA i.v. and 100 mg kg-' CP94 i.v., (D) administration of 100 mg kg-'
CP94 30 min before 50 mg kg-' ALA i.v., (E) simultaneous administration of 50 mg kg-' ALA i.v. and 100 mg kg-' CP20 i.v. and (F) administration of 100 mg kg-'
CP20 30 min before 50 mg kg-' ALA i.v. Each point represents the mean values from two separate animals
and ALA solutions even when administered at the same time and
all injections were made under general anaesthetic in different
veins to avoid any potential interactions between the compounds.
No adverse effects were observed when administering any of the
compounds.
Animal model
Normal, female, Wistar rats (120-200 g) supplied by the Imperial
Cancer Research Fund (London, UK) were used throughout. The
animals were anaesthetized for all parts of the procedure
using inhaled halothane (ICI Pharmaceuticals, Cheshire, UK)
and analgesia was administered subcutaneously after surgery
(Buprenorphine hydrochloride, Reckitt & Colman Products Ltd,
Hull, UK).
Fluorescence studies
ALA (50 mg kg-' i.v.) and CP20 (100 mg kg-' i.v.) or CP94
(100 mg kg-' i.v.) were administered separately or in various
combinations under general anaesthetic. The animals were then
recovered and killed serially at various times after injection
(30-240 min). Sections of colon were removed and snap frozen in
liquid nitrogen. Ten micrometre thick cryosections were prepared,
together with adjacent sections for haematoxylin and eosin (H and
E) staining.
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Phase contrast microscopy with a slow-scan cooled charge-
coupled device (CCD) camera (Wright Instruments, Enfield,
London, UK) was used to image and quantify fluorescence on the
frozen sections. The fluorescence was excited using an 8-mW
helium-neon laser (632.8 nm) and detected between 665 and
710nm using bandpass and longpass filters as described previ-
ously (Bedwell et al, 1992). A false colour-coded image of the
fluorescence signal in counts per pixel was produced and the fluo-
rescence intensity in each tissue layer was quantified digitally, by
averaging over specified areas. All fluorescence measurements
were corrected for background autofluorescence and structures
were identified by correlation with the adjacent H and E-stained
section. Two measurements were made and averaged per section
and two animals were treated with each set of parameters. Intensity
calibrations were performed using a 0.1-mm-thick ruby disc which
emits near 690 nm under 633 nm excitation. A previous study
using the same system (Loh et al, 1993) on normal rat colon using
intravenous ALA has demonstrated that the CCD fluorometric
measurements of porphyrin fluorescence correlate well with
chemical extraction measurements.
Fluorescence emission spectra were also recorded from separate
representative frozen sections to confirm that the fluorescence
observed in the imaging was indeed produced by PPIX and no other
fluorescent compound. This was carried out by connecting a spec-
trograph (Multispec 1/8 m, Oriel Instruments, Connecticut, USA)
with a slow-scan cooled CCD camera (600 x 400 pixels, Wright
Instruments) via a fibre-optic bundle to an inverted microscope.
Fluorescence was excited using a 1-mW helium-neon laser at
543 nm and emission spectra were recorded over the range 615-
735 nm with 1 nm resolution. Scattered excitation light was
suppressed using a RG590 filter and a grating blazed at 650 nm
gave a relatively uniform detection efficiency over the range 615-
735 nm, so the spectra presented are uncorrected. Epifluorescence
excitation was confined to a spot (100,m diameter) which was
aligned (using phase contrast microscopy) to a region of interest.
No photobleaching effects were observed (i.e. no diminution of the
porphyrin spectra and/or photoproduct emission) with the short
integration times (10 s) used to record the spectra in this study.
PDT studies
All animals were given 50 mg kg-' ALA intravenously, 75 min
before surgery. CP94 (100 mg kg-') i.v. was given at times from
30 min before, to 60 min after the ALA dose. PDT was conducted
at laparotomy. The light source was a pulsed (12 kHz) copper
vapour pumped dye laser (Oxford lasers, Oxford, UK) tuned to
635 nm. A total energy of 100 J was delivered via a 200-,um plane
cleaved optical fibre (output power, 100 mW) passed through the
antimesenteric colon wall (approximately 1 cm distal to the
caecum), so that it just touched the mucosa of the opposite side
(area of contact = 0.000314 cm2). This is a model that we have
used many times successfully in the past. The light fluence where
the fibre touches the tissue is very high (320 W cm-2), but no
thermal effect was observed in the light only control group. As the
light fluence falls off rapidly with increasing distance along the
colon wall from the fibre tip, measuring the diameter of the zone of
necrosis in the wall of the colon is a convenient way of comparing
the efficacy of PDT necrosis with different treatment parameters.
The rest of the abdominal viscera were shielded from forward light
scatter by a piece of opaque paper positioned so that it did not
touch the colon or affect its light distribution.
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Figure 2 Emission spectra obtained from the mucosal layer of frozen colon
sections from the following treatment groups: (A) 50 mg kg-' ALA i.v., 75 min
after administration, (B) 50 mg kg-' ALA i.v. and 100 mg kg-' CP94 i.v.,
75 min after simultaneous administration and (C) 50 mg kg-' ALA i.v. and
100 mg kg-' CP20 i.v., 75 min after simultaneous administration
All animals were recovered after surgery and killed after 3 days,
as mucosal damage is maximal at this time (Barr et al, 1987). The
treated area of colon was excised, cut longitudinally and flattened
out so that the lesion produced by the treatment could be
photographed with a scale. This image was then scanned into a
computer using a flat-bed scanner and image process software was
used to determine the size of the area of necrosis, in the plane
perpendicular to that of the treatment fibre. Representative speci-
mens were fixed in formalin so that conventional light microscopy
could confirm the macroscopic findings. This end point enabled a
direct comparison of the treatment groups so that the most effec-
tive regime (the one which produced the most necrosis) could be
determined.
RESULTS
Tissue fluorescence quantification
Figure 1 shows how the fluorescence in the colonic mucosa and
muscle varied with time after each regime of drug administration.
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Figure 3 Mean area of necrosis (mm2) as a function of the PDT treatment
regime. 100 mg kg-' CP94 i.v. was administered at various times relative to
50 mg kg-' ALA i.v. which was given 75 min before 100 J of 635-nm light
(100 mW). Each group represents the mean (with the standard error of the
mean) from eight separate animals
The fluorescence profile in this model after administration of
50 mg kg-' ALA i.v. alone (Figure IA) shows that the level of
fluorescence is considerably higher in the mucosa than the under-
lying muscle and peaks at 75 min (the time chosen for photody-
namic studies). Figure lB shows the level of fluorescence
produced if the iron-chelating agents are administered without
ALA. There is a slight increase in fluorescence (particularly at 75
min) resulting from the effect of the iron chelators on the normal
endogenous haem biosynthetic pathway. It should be noted that the
background autofluorescence of the endogenous porphyrins from
the colon of untreated control animals has been subtracted from all
fluorescence measurements.
The simultaneous administration of CP94 with ALA (Figure
1C) doubles the peak fluorescence produced in the colonic
mucosa. The fluorescence in the muscle does not increase signifi-
cantly and remains low, resulting in a large difference between the
mucosal and muscle layers. By administering CP94 30 min before
ALA (Figure 1D), the enhancement of mucosal fluorescence is
slightly reduced but it appears that the profile might change, so
there is potentially a larger therapeutic window in which PDT
treatment could be conducted.
Figure IE and F shows the same treatment regimes but with
CP20 instead of CP94. Although both treatments produce greater
mucosal fluorescence than ALA alone, they do not produce the
same degree of enhancement as CP94.
Fluorescence spectroscopy
Fluorescence spectra were recorded using the microscope from
frozen sections of tissue taken from animals given each treatment
regime and representative spectra from mucosal areas are shown in
Figure 2. The spectra from blank control sections (no compounds
injected) were subtracted. There are no significant differences
between the ALA only (Figure 2A) and combinations of CP94 and
ALA (Figure 2B) or CP20 and ALA (Figure 2C) spectra, or in fact
any other spectra recorded during this study, which demonstrates
that the iron-chelating agents do not induce significant production
of other fluorescent species. Maxima were at 636±2 nm in each
case and the spectral profiles recorded conform to the standard
PPIX emission spectra described by Dietel et al (1997) and Sailer
et al (1997). A previous high-performance liquid chromatography
(HPLC) analysis of colon samples after intravenous administration
of ALA to Wistar rats (Loh et al, 1993) has shown that PPIX is the
predominant porphyrin present (>95%) and we can, therefore,
conclude that the fluorescence measured in our present study is
produced predominantly by PPIX.
Photodynamic effects
The area of necrosis (mm2) produced by each treatment regime is
plotted in Figure 3. Only the effects of CP94 on ALA-induced PDT
were investigated because it was found to be the more promising
iron chelator in the fluorescence studies. The time of CP94 adminis-
tration relative to ALA administration was varied and the success of
the PDT treatment regime determined by the area of necrosis
produced. The simultaneous administration of 50 mg kg-' ALA i.v.
and 100 mg kg-' CP94 i.v. was found to be the most effective,
producing three times the area of necrosis ofALA alone. CP94 only
plus light controls, laser only controls and drug only controls were
also conducted, none of which produced any necrosis. The error
bars were determined by calculating the standard error of the mean.
Histological analysis of fixed sections showed necrosis in all the
treated groups. This was full thickness in places. It is likely that
this occurred (even though the level of PPIX is much lower in the
colonic muscle than the colonic mucosa) because of the high inci-
dent fluence rate used in this model, as well as the thinness of the
rat colon. A combination of these factors may have allowed a
sufficient level of light to penetrate into the muscle to cause
necrosis. Even though full thickness necrosis was observed in
some sections and large lesions (relative to the size of the rat
colon) were produced in some cases, no animal showed evidence
of colonic perforation or stenosis at post mortem (even though
occasional lesions were circumferential) and no other abdominal
organs appeared affected by the treatment.
DISCUSSION
PDT using ALA is limited clinically by the ALA dose which can
be tolerated orally. It is thought that the transient elevation of liver
enzymes found after oral administration of ALA is related to the
high levels of ALA reaching the liver after absorption from the
upper gastrointestinal tract. This is most probably due to the ALA
itself, although it is difficult to be sure it is not due to the PPIX
produced from the ALA. If it is due to the ALA, one way to over-
come this problem may be the administration of an iron-chelating
agent in combination with the ALA, as reported here. This
enhances the effect of the treatment, producing more necrosis,
without increasing the administered dose of ALA. This method
further manipulates the haem biosynthetic pathway, as not only is
the normal regulation of the pathway being avoided, by the exoge-
nous administration of ALA resulting in all subsequent enzymes
being forced to operate at maximal rate, but the iron chelator also
inhibits the final step of the pathway (and the secondary rate-
limiting point) by removing Fe2+ from the system. This results in
an even greater accumulation of PPIX, which can then be utilized
for PDT. In addition to this, the resultant low intracellular iron
concentration also inhibits translation of ALA synthase mRNA,
which would normally (without exogenous ALA administration)
be a major point of regulation for this pathway (Cox et al, 1991).
The hydroxypyridinones are a relatively new series of iron chela-
tors which are well suited to this application by having lower mole-
cular weights and greater lipophilicity than desferrioxamine, a
clinically established iron chelator (Brittenham, 1992). Both CP94
and CP20, the hydroxypyridinones investigated in this study, have
British Joumal of Cancer (1998) 78(10), 1278-1282
1 13r _12b
WIP Cancer Research Campaign 1998
1282 A Cumow et al
been administered orally to humans and have been seen to be
absorbed rapidly and completely from the gastrointestinal tract.
entering cells by simple diffusion (Hoyes and Porter. 1993). Both
CP2O and CP94 can be alucuronidated in humans and then excreted
in unne. which is not possible in rats. so they are more rapidly
cleared in patients (Porter et al. 1993.) CP94 is a more effective iron
chelator than CP2O as it has greater lipophilicity. it can therefore
access the intracellular iron pools and inhibit metalloenzymes (such
as lipoxygenase and ribonucleotide reductase) more rapidly than
CP2O (Abevsinghe et al. 1996 and Cooper et al. 1996). It has
greater affinity for iron than desferroxamine beina bidentate
(rather than hexadentate). bindinc to iron in the ratio of 3:1
compared with 1: 1 with desferrioxamine (Hershko et al. 1991).
Beino a relatively new series of compounds. relatively little
research has been conducted investioatin2 the effects of the
hydroxypyridinones on ALA-induced PDT. We have. however.
previously found that CP94 enhanced porphyrin fluorescence and
photosensitivity in all cell lines studied (Bech et al. 1997). as well
as doubling, the PPIX fluorescence in the urothelium of the normal
rat bladder (when aiven in combination with ALA instilled in the
bladder) (Chang et al. 1997). Other iron chelators such as
ethvlenediamine tetraacetic acid (EDTA) and desferrioxamine
have been investigated more extensively (Smetana et al. 1997)
and. although they too have positive effects on ALA-induced PDT.
thev are less effective iron chelators than the hydroxypyridinones.
In this study. the CCD fluorescence microscopy determined
that the more lipophilic iron-chelating agent. CP94. was more
effective at increasing the mucosal PPIX fluorescence. producing
twice that of ALA alone. when the two were aiven simultaneously.
confirming our previous observations in the bladder. The time of
peak fluorescence (and. therefore. the optimum time of light dose
administration) was the same as after ALA alone. The muscle fluo-
rescence was not increased sianificantlv by the administration of
the iron chelators. so the selectivity between the different tissue
layers was maintained. Microspectrofluorimetrv using 543 nm
excitation confirmed that the fluorescence observed could be
attributed to PPIX and not water-soluble porphvrins (e.g. uro- or
copro-) or other fluorescent metallated porphyrins (also excited by
543 nm). which could be produced by the altered biochemistrv
induced by these compounds. This is an important point because
ferrochelatase. in an iron-deficient environment, can insert other
metal ions instead of iron (Kennedy et al. 1996).
We found it possible to convert the increased fluorescence
observed in the pharmacokinetic study into increased necrosis with
PDT. with a substantial threefold amplification being observed
with the simultaneous administration of CP94 and ALA when
compared with ALA alone. Although several different times of
CP94 administration were investigated. this was found to be the
most effective treatment regime and may be of value clinically.
Further study is. however. necessarv. and should include oral or
topical application of CP94 in combination with ALA and the
effects of these compounds in a tumour model in which the iron
metabolism may be altered. We have. nonetheless. established that
the iron-chelating agent. CP94. can be used to significantly
increase the area of necrosis produced by ALA-induced PDT. in
this model. without requiring an increase in the administered dose
of ALA. Both iron-chelating agents have been administered intra-
venouslv in this study which is a convenient, accurate method of
administration in this species. As all the compounds used in this
study are normally administered orally to patients. further study
with this mode of administration should be conducted.
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